Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 16Other hematologic neoplasm 5Lymphoid 5Genitourinary 5Gastrointestinal 4Thoracic 2Plasma cell 2Other neoplasm 2Gynecologic 2Sarcoma 1Head & Neck 1Dermatologic 1

Conditions

Smoldering Multiple Myeloma 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1

Interventions

Dexamethasone 882Bortezomib 481Lenalidomide 467Cyclophosphamide 367Melphalan 276Calcium Dobesilate 265daratumumab 241pomalidomide 216carfilzomib 188fludarabine phosphate 141fludarabine 137Thalidomide 125Peripheral Blood Stem Cell Transplantation 120Filgrastim 115ixazomib 94Mycophenolic Acid 91Granulocyte Colony-Stimulating Factor 90Busulfan 89Whole-Body Irradiation 88dexamethasone acetate 87Tacrolimus 79dexamethasone 21-phosphate 74isatuximab 70Cyclosporine 68auricularum 67Prednisone 67elotuzumab 63belantamab mafodotin 60Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Fatty Acids, Omega-3 × Plasma cell × Clear all
NCT00003077 2016-07-13

Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss

Alliance for Clinical Trials in Oncology

Phase 1/2 Completed
63 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Neoplasms, Plasma Cell

NCT00899353 2013-12-12

Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)

Marshall University

Phase 2 Terminated
16 enrolled 6 charts
LymphoidOther hematologic neoplasmPlasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡